NYSE:ALT - Altimmune Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.09 -0.81 (-5.83 %)
(As of 09/25/2018 04:00 PM ET)
Previous Close$13.90
Today's Range$12.55 - $14.27
52-Week Range$4.27 - $94.80
Volume181,300 shs
Average Volume59,505 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ALT
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,280,000
Market Cap$0.00

Altimmune (NYSE:ALT) Frequently Asked Questions

What is Altimmune's stock symbol?

Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT."

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NYSE:ALT) announced its earnings results on Tuesday, August, 14th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $3.01 million. View Altimmune's Earnings History.

When is Altimmune's next earnings date?

Altimmune is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Altimmune.

What is the consensus analysts' recommendation for Altimmune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Altimmune.

Who are some of Altimmune's key competitors?

Who are Altimmune's key executives?

Altimmune's management team includes the folowing people:
  • Mr. William J. Enright, Pres, CEO & Director (Age 55)
  • Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)
  • Dr. Sybil Tasker, Chief Medical Officer (Age 55)
  • Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $13.09.

What is Altimmune's official website?

The official website for Altimmune is http://www.altimmune.com.


MarketBeat Community Rating for Altimmune (NYSE ALT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  50
MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote "Outperform" if you believe ALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel